Uq0336c4b OA.Pdf

Total Page:16

File Type:pdf, Size:1020Kb

Uq0336c4b OA.Pdf DR NATASHA A KOLOSKI (Orcid ID : 0000-0002-8647-5933) PROFESSOR MARJORIE M WALKER (Orcid ID : 0000-0002-7788-0056) PROFESSOR G.J. HOLTMANN (Orcid ID : 0000-0002-0206-2358) Article type : Original Scientific Paper Submitted to: Alimentary Pharmacology & Therapeutics Date: 18 November 2018 -Revised 1 Population based study: Atopy and autoimmune diseases are associated with functional dyspepsia and irritable bowel syndrome, independent of psychological distress. Running title: Atopy, autoimmune disorders, functional dyspepsia and IBS Koloski Natasha,1-4 Jones Michael, 2,5 Walker Marjorie M,,1,2 Veysey Martin, 1 Zala Alkesh,6 Keely Simon, 1-2 Holtmann Gerald, 1,4 Talley Nicholas J 1,2, 6 1. Faculty of Health and Medicine, University of Newcastle, Newcastle, NSW, Australia 2. Australian Gastrointestinal Research Alliance (AGIRA) 3. Department of Gastroenterology, Princess Alexandra Hospital, Woolloongabba, QLD, Australia 4. School of Medicine, University of Queensland, St Lucia, QLD, Australia Author Manuscript 5. Macquarie University, Sydney, NSW, Australia. This is the author manuscript accepted for publication and has undergone full peer review but has not been through the copyediting, typesetting, pagination and proofreading process, which may lead to differences between this version and the Version of Record. Please cite this article as doi: 10.1111/apt.15120 This article is protected by copyright. All rights reserved 6. Department of Gastroenterology, John Hunter Hospital, New Lambton, NSW, Australia Correspondence and Reprints: Prof Nicholas Talley Faculty of Health & Medicine University of Newcastle Callaghan NSW 2305 Australia Email: [email protected] Grant Support This study was supported by a grant from Prometheus laboratories Specific author contributions: NAK was involved in study concept and design; acquisition of data; analysis and interpretation of data; critical revision of the manuscript for important intellectual content MJ was involved in study concept and design; analysis and interpretation of data; critical revision of the manuscript for important intellectual content; statistical analysis MMW was involved in study concept and design; analysis and interpretation of data; drafting of the manuscript; critical revision of the manuscript for important intellectual content. MV was involved in acquisition of data and critical revision of the manuscript for important intellectual content AZ was involved in acquisition of data and critical revision of the manuscript for important intellectual content SK was involved in study concept and design; critical revision of the manuscript for important intellectual content; statistical analysis. GH was involved with analysis and interpretation of data; drafting of the manuscript; critical revision of the manuscript for important intellectual content. NJT was involved in study concept and design; analysis and interpretation of data; drafting of the manuscript; critical revision of the manuscript for important intellectual content; study supervision. Author Manuscript Disclosures: This article is protected by copyright. All rights reserved NAK: None to disclose MPJ: Consultancies with GI Therapies (abdominal stimulation in constipation), SFI (prokinetics). MMW: Grant/Research Support: Prometheus Laboratories Inc [Irritable bowel syndrome (IBS Diagnostic), Commonwealth Diagnostics International (Biomarkers for FGIDs) MV: None to disclose AZ: None to disclose SK: Grant/Research Support: Cancer Institute NSW (Career Development Fellowship), National Health and Medical Research Council (Project Grant APP1128487) Commonwealth Diagnostics International (Biomarkers for FGIDs), Syntrix Biosystems (contract research - drug delivery). Consulting/Advisory Boards: Gossamer Bio, Aerpio Therapeutics GH: Unrestricted educational support from Bayer Ptd, Ltd and the Falk Foundation. Research support was provided via the Princess Alexandra Hospital, Brisbane by GI Therapies Pty Limited, Takeda Development Center Asia, Pty Ltd, Eli Lilly Australia Pty Limited, F.Hoffmann-La Roche Limited, MedImmune Ltd Celgene Pty Limited, Celgene International II Sarl, Gilead Sciences Pty Limited, Quintiles Pty Limited, Vital Food Processors Ltd, Datapharm Australia Pty Ltd Commonwealth Laboratories, Pty Limited, Prometheus Laboratories, Falk GmbH and Co Kg, Nestle Pty Ltd, Mylan. Patent Holder: A biopsy device to take aseptic biopsies (US 20150320407 A1) NJT: Grant/Research Support: Rome Foundation; Abbott Pharmaceuticals; Datapharm; Pfizer; Salix [Irritable bowel syndrome]; Prometheus Laboratories Inc [Irritable bowel syndrome (IBS Diagnostic)]; Janssen [Constipation]. Consultant/Advisory Boards: Adelphi Values [Functional dyspepsia (patient-reported outcome measures)]; (Budesonide)]; GI therapies [Chronic constipation (Rhythm IC)]; Allergens PLC; Napo Pharmaceutical; Outpost Medicine; Samsung Bioepis; Yuhan [IBS]; Synergy [IBS]; Theravance [Gastroparesis]. Patent Holder: Biomarkers of irritable bowel syndrome [Irritable bowel syndrome] Licensing Questionnaires [Mayo Clinic Talley Bowel Disease Questionnaire - Mayo Dysphagia Questionnaire]; Nestec European Patent [Application No. 12735358.9]; Singapore ‘Provisional’ Patent [NTU Ref: TD/129/17 “Microbiota Modulation Of BDNF Tissue Repair Pathway]. Summary Background: The pathogenesis of functional GI disorders (FGIDs) is uncertain. However, underlying immune activation and psychological distress has been documented in irritable bowel syndrome (IBS)Author Manuscript and functional dyspepsia (FD). Epidemiological data from the UK suggest FGIDs are linked to atopy and certain autoimmune diseases but this has not been confirmed. This article is protected by copyright. All rights reserved Aims: In a large population-based study we aimed to test if allergic or autoimmune diseases are independently associated with FGIDs, irrespective of psychological distress. Methods: A total of 3,542 people (mean age 57.9 years and 52.7% females) randomly selected from the Australian population, returned a mail survey (response rate = 43%). The survey asked about a physician diagnosis of autoimmune disease (scleroderma, psoriasis, rheumatoid arthritis and diabetes mellitus) or allergic conditions (asthma, food, pollen and/or animal allergy). The questionnaire assessed psychological distress and Rome III criteria for FD and IBS. Results: Asthma, food, pollen and animal allergies, psoriasis and rheumatoid arthritis were univariately significantly associated with IBS and FD. Food allergy (OR=1.66;95%CI 1.15- 2.40, P=0.007), psoriasis (OR=1.81;95%CI 1.19-2.74, P=0.006) and rheumatoid arthritis (OR=1.68;95%CI 1.15-2.4, P=0.007) were independent risk factors for IBS, controlling for age, sex and psychological distress. In FD, asthma (OR=1.32;95%CI 1.04-1.68, P=0.025) and food allergy (OR=1.78;95%CI 1.28-2.49, P=0.001) were independent predictors, controlling for age, sex and psychological distress. Conclusions: There is evidence that both atopic and autoimmune diseases are risk factors for FGIDs, independent of psychological distress, differing in IBS and FD. This provides evidence that different peripheral pathways may be involved in the pathogenesis of certain FGIDs. Keywords Functional gastrointestinal disorders; allergy; autoimmune disease; psychological distress Introduction Irritable bowel syndrome (IBS) and functional dyspepsia (FD) are the most common functional gastrointestinal disorders (FGIDs) affecting up to 20% of the general population.1 Treatment alleviates, but does not cure symptoms. 2 Recent research suggests that immune activation is likely a key player in the development of these disorders. 3-7 Evidence for innate immune activation in the mucosa in IBS and FD has been observed 6-7 but the prevalence of Author Manuscript immune activation in FGIDs is uncertain. An alternative approach examining the potential role of immune activation in FGIDs is to ascertain the prevalence of IBS and FD occurring alongside other conditions in the general population known to be associated with immune This article is protected by copyright. All rights reserved dysregulation. A study from the UK, which evaluated 23,471 patients from the General Practice Research Database, found evidence for increased prevalence of immune and autoimmune disorders and IBS and functional dyspepsia. 8-9 It was found that there was an increased probability of a diagnosis of functional dyspepsia in those with immune related disorders such as rheumatological autoimmune diseases including rheumatoid arthritis, seronegative arthritis, psoriatic arthritis and ankylosing spondylitis. 8 Autoimmune conditions such as rheumatoid arthritis and psoriasis have a predominant T-helper-1 and T-helper-17 type immune response. 10-11 An excessive T-helper-1 response has also been observed in some cases of IBS. 12 Most of these studies however have been patient based and it is unknown whether these and other autoimmune diseases such as psoriasis and scleroderma are also associated with a diagnosis of IBS and FD in the general population. By contrast, atopy is characterised by a predominant T-helper-2 type immune response. In atopy (including asthma, eczema rhinitis/hay fever) an underlying disordered T-helper-2 immune responses occurs 13 and this also may happen in a subset of FGIDs. 14 Data obtained from birth cohort studies and patient- based studies have suggested that atopy is associated with both IBS and FD. 9,13-21 However, the role of specific allergies in FGIDs is less clear. A reaction to wheat proteins
Recommended publications
  • 9781920898359 Appendices R
    319 Appendix 1 University leadership Fellows of the Senate Students, Deputy Chair of Academic Staff or Alumni of the Board from 1980 Faculty from 1980 1978–1980 John Young 1978–1981 John Young 1986 Susan Dorsch 1979–1993 Katherine Georgouras 1986–1987 Ann Sefton 1983–1986 Andrew Refshauge 1991–1993 Alan Pettigrew 1986–1987 Diana Temple 1992–1996 James Lawrence 1987 Alan Cass 1996 Ann Sefton 1989 Anna Donald 1989 Tony Sara Senate Deputy Chancellor 1989 Eric Wegman from 1980 1990–1991 Natalie Smith 2004– Ann Sefton 1993–1995 Douglas Baird 1995–2002 Stephen Leeder 1996–2001 Michael Copeman 1997– Robin Fitzsimons 1997–2001 Peter Burrows 2001– Ann Sefton 2005– Michael Copeman 320 Appendix 2 Deans of the Faculty of Medicine from 1980 1974 –1989 Richard S Gye 1989 –1996 John Atherton Young 1997–2002 Stephen Leeder 2003 – Andrew Coats Appendix 3 Current Emeritus Professors Barry Baker John Little Tony Basten William McCarthy Geoffrey Berry James McLeod Charles Blackburn Russell Meares Charles Bridges-Webb Gerald Milton Neil Buchanan Kim Oates Peter Castaldi Murray Pheils John Chalmers Wai-On Phoon Patrick De Burgh Thomas Reeve Susan Dorsch Douglas Saunders Hans Freeman Ann Sefton Kerry Goulston Ainslie Sheil Richard Gye Frederick Stephens Akos Gyory Michael Taylor Noel Hush Thomas Taylor Gordon Johnson Stewart Truswell Charles Kerr John Turtle James Lawrence Robert Wake 321 Appendix 4 Professors appointed or promoted 1980–2005 1980 W Cramond 1989 Nicholas Hunt 1994 Leigh Delbridge 1980 Graeme Johnston 1989 John Sutton 1994 Ian Frazer 1980 Philip
    [Show full text]
  • Laureate Professor Nicholas Talley
    CHAIR: Laureate Professor Nicholas Talley Professor Talley is currently Pro Vice-Chancellor, Global Research at the University of Newcastle, Australia. He is an expert clinician, educator and researcher. He has published over 890 original and review articles in the peer-reviewed literature, and is considered one of the world’s most influential clinician-researchers, and is also a leading medical educator and the author of the highly regarded textbooks Clinical Examination and Examination Medicine. In June 2014, Professor Talley was inaugurated as one of the first 15 Fellows of the Australian Academy of Health and Medical Sciences (FAHMS) and was elected to the Executive of the Academy. He has held roles as Co-Editor-in-Chief of Alimentary Pharmacology and Therapeutics for 6 years, and completed two 3- year terms (as Co-Editor-in-Chief of the American Journal of Gastroenterology. He is a Section Editor for the on-line textbook Up To Date. Professor Talley was formerly Professor of Medicine and Professor of Epidemiology and Chair of the Department of Internal Medicine at Mayo Clinic in Florida, USA, and previously Foundation Professor of Medicine at the University of Sydney. Professor Talley is a Staff Specialist Gastroenterologist at John Hunter Hospital and current researcher with the Mayo Clinic, University of North Carolina and the Karolinska Institute. He is a Fellow and Past President of the Royal Australasian College of Physicians; Fellow the Royal College of Physicians (both London and Edinburgh), the American College of Physicians, the American College of Gastroenterology and the AGA. He is the recipient of a number of prestigious awards.
    [Show full text]
  • Aetiopathogenesis of Functional Dyspepsia
    NZ 2019 Aetiopathogenesis of functional dyspepsia Genetic DUODENAL LUMEN predisposition GUT EPITHELIUM BRAIN ↑ Epithelial permeability Pathogens or allergens Anxiety or stress response APC Eotaxin release LAMINA PROPRIA Eosinophil activation Disordered motility and visceral hypersensitivity Immune cells Th2-cell Interleukin-4 response Interleukin-13 Interleukin-5 Early satiety Eosinophil degranulation B-cell response ↑ Inflammatory cytokines TNFα, Eosinophil interleukin-10, and Epigastric recruitment interleukin-1β Release of Nerve proallergic IgE pain, infringement DUODENUM Delayed gastric emptying burning Nerve firing Muscle contractions Fullness post and pain Talley & Ford.MUSCL NE FIBER EnglS J Med 2015:373:1853-63 meal Nicholas J. Talley AC, MD, PhD University of Newcastle, Australia Disclosures Grant / Research Support Committees Commonwealth Diagnostics (International) (IBS) Australian Medical Council (AMC) Council Member (ceased 2017) MBS Review Taskforce NHMRC Principal Committee, Research Committee HVN National Science Challenge NZ (no financial Asia Pacific Association of Medical Journal Editors (APAME) support) Patents Consultancies Biomarkers of irritable bowel syndrome (#12735358.9 - Takeda (gastroparesis) 1405/2710383 and (#12735358.9 -1405/2710384) Adelphi values (functional dyspepsia working group to develop a symptom based PRO instrument) Licensing Questionnaires (Mayo Clinic) Talley Bowel Disease Questionnaire, Mayo Dysphagia Questionnaire Allergens PLC GI therapies (non-invasive device company, consultant and Nestec European Patent Application No. 12735358.9 options) Singapore ‘Provisional’ Patent NTU Ref: TD/129/17 IM Health Sciences, USA “Microbiota Modulation of BDNF Tissue Repair Napo Pharmaceutical Pathway” Outpost Medicine Editorial Samsung Bioepis Synergy Medical Journal of Australia (Editor-in-Chief) Theravance Up to Date (Section Editor) Avant Foundation (judging of research grants) Precision and Future Medicine, Sungkyunkwan University School of Medicine, South Korea Community and patient advocacy groups Boards GESA Board Member.
    [Show full text]
  • MJA Editor-In-Chief Is Australia's Most Cited Academic
    MJA Editor-In-Chief is Australia’s most cited academic Australia’s leading medical journal – with a 5-year impact factor of 4.1 – is headed by the country’s top researcher from the University of Newcastle, according to a new report from Google Scholar . The Medical Journal of Australia’s Editor-in-Chief Laureate Professor Nicholas Talley is the highest ranking in a list of the top 1,000 scientists from Australian institutions according to their Google Scholar Citations profiles . The researchers are ranked by h-index, which combines measures of both their productivity and citation impact. Professor Talley is a global authority in neurogastroenterology and incurable functional gut disorders that affect more than one in five Australians. His recent work linking the gut as a major driver of anxiety and other changes in the brain has contributed to a paradigm shift in the way we understand how the gut interacts with the brain. This new approach may eventually unlock new therapies not just for gut conditions, but also for intractable neurodegenerative diseases such as Parkinson’s. Professor Talley’s groundbreaking work with Professor Marjorie Walker at the University of Newcastle has led to the discovery of two new gut diseases in conditions that were previously thought to have no known cause: duodenal eosinophilia in dyspepsia, and large bowel eosinophilia linked to colonic bacteria in irritable bowel syndrome (IBS). His other major work has identified a link between autoimmune and unexplained gut disease , which could lead to new treatment approaches. His team is investigating the role of environmental and dietary factors including wheat in causing these gut problems.
    [Show full text]
  • Clinical Examination a Systematic Guide to Physical Diagnosis
    7 EDITION clinical examination A systematic guide to physical diagnosis Nicholas J Talley and Simon O’Connor sample proofs © Elsevier Australia clinical examination A systematic guide to physical diagnosis Seventh edition Nicholas J Talley MB BS (Hons), MMedSc (Clin Epi) (Newc), MD (NSW), PhD (Syd), FRACP, FAFPHM, FRCP (Lond), FRCP (Edin), FACP, FACG, AGAF Pro Vice-Chancellor and Dean (Health and Medicine), and Professor, University of Newcastle, Callaghan, NSW, Australia; Senior Staff Specialist, John Hunter Hospital, Newcastle, NSW, Australia; Adjunct Professor of Medicine, Mayo Clinic, Rochester, MN, United States; Adjunct Professor of Medicine, University of North Carolina, United States; Foreign Guest Professor, Karolinska Institute, Sweden; President-Elect, Royal Australasian College of Physicians Simon O’Connor FRACP, DDU, FCSANZ Cardiologist, The Canberra Hospital; Clinical Senior Lecturer, Australian National University Medical School, Canberra, ACT, Australia Sydney Edinburgh London New York Philadelphia St Louis Toronto sample proofs © Elsevier Australia Churchill Livingstone is an imprint of Elsevier Elsevier Australia. ACN 001 002 357 (a division of Reed International Books Australia Pty Ltd) Tower 1, 475 Victoria Avenue, Chatswood, NSW 2067 This edition © 2014 Elsevier Australia 6th edn 2010; 5th edn 2006; 4th edn 2001; 3rd edn 1996; 2nd edn 1992; 1st edn 1988 eISBN: 9780729581479 This publication is copyright. Except as expressly provided in the Copyright Act 1968 and the Copyright Amendment (Digital Agenda) Act 2000, no part of this publication may be reproduced, stored in any retrieval system or transmitted by any means (including electronic, mechanical, microcopying, photocopying, recording or otherwise) without prior written permission from the publisher. Every attempt has been made to trace and acknowledge copyright, but in some cases this may not have been possible.
    [Show full text]
  • MJA Editor-In-Chief Wins Top Honour Top Wins Editor-In-Chief MJA L C2 MJA 208 (3) • 19 February 2018 Dr Davidsinclair: and Care
    Careers MJA editor-in-chief wins top honour Professor Nick Talley, editor-in-chief of the MJA, is one of six medical practitioners to win the country’s highest honour, Companion in the General Division of the Order of Australia … AUREATE Professor Nicholas Talley, University of the same time minimise waste and reduce costs. We can easily Newcastle, NSW, and editor-in-chief of the Medical Journal become complacent about health but that would be wrong, Lof Australia, has been named a Companion (AC) in the because we can be better.” General Division of the Order of Australia. Professor Talley is a household name to many doctors in Professor Talley’s citation reads: Australia today. His medical textbooks, along with co-author “For eminent service to medical Dr Simon O’Connor, are used in nearly every medical school research, and to education in the across Australia and many internationally. field of gastroenterology and He has been instrumental in guiding peer-reviewed epidemiology, as an academic, medical publications. He was editor of the American Journal author and administrator at of Gastroenterology from 2004 to 2009; editor of Alimentary the national and international Pharmacology and Therapeutics from 2009 to 2015; and, has been level, and to health and scientific editor-in-chief of the MJA since 2015. associations.” Professor Talley said he could not have accepted so many Currently Pro Vice-Chancellor “extra-curricular” roles without the help of the University of (Global Research) at the University Newcastle (UoN). of Newcastle, and a senior staff specialist in gastroenterology at “I have to thank UoN for their fantastic support,” he said.
    [Show full text]
  • Functional Dyspepsia
    VOLUME 40 : NUMBER 6 : DECEMBER 2017 ARTICLE Functional dyspepsia Nicholas J Talley SUMMARY Laureate professor1 Pro‑vice‑chancellor1 Functional dyspepsia is characterised by troublesome early satiety, fullness, or epigastric pain Thomas Goodsall or burning. It can easily be overlooked as the symptoms overlap with gastro-oesophageal reflux Conjoint research fellow1 disease and irritable bowel syndrome. Registrar2 Diagnosis is clinical, however it requires exclusion of structural gastrointestinal disease. Michael Potter The presence of red flags, such as weight loss or anaemia, should prompt investigation Conjoint research fellow1 including gastroscopy. Registrar2 The pathophysiology of functional dyspepsia is not completely understood. It is thought to be 1 Global Research associated with upper gastrointestinal inflammation and motility disturbances, which may be University of Newcastle triggered by an infectious or allergenic agent, or a change in the intestinal microbiome. Slow 2 Department of gastric emptying occurs in 20% of cases. Gastroenterology John Hunter Hospital While functional dyspepsia is distressing and affects quality of life, it has no long-term impacts Newcastle on mortality. New South Wales There are many treatment options available, with varying levels of evidence of efficacy. These Keywords include reassurance, dietary modification, acid suppression, prokinetic drugs including fundic dyspepsia, endoscopy, relaxors, tricyclic antidepressants, rifaximin and psychological therapy. gastro‑oesophageal reflux, H2 receptor antagonists, proton pump inhibitors Introduction gastroscopy, and are labelled as having functional or 4,6 Functional dyspepsia is a common problem in non-ulcer dyspepsia. Aust Prescr 2017;40:209–13 Australia and often impacts on quality of life and work Correctly diagnosing functional dyspepsia is productivity.1,2 It affects 10% of the population and is important to guide appropriate therapy and reduce https://doi.org/10.18773/ austprescr.2017.066 more prevalent in women.3-5 unnecessary procedures or treatments.
    [Show full text]
  • Physicians' Preferences for Hospice If They Were Terminally Ill and The
    Letters in 5.6% and 0.36%, respectively, only marginally less than the 6. Vakil N, Moayyedi P, Fennerty MB, Talley NJ. Limited value of alarm features prevalence in those with symptomatic GERD.7 in the diagnosis of upper gastrointestinal malignancy: systematic review and meta-analysis. Gastroenterology. 2006;131(2):390-401. The difficulty in identifying the right patients with GERD 7. Rex DK, Cummings OW, Shaw M, et al. Screening for Barrett’s esophagus in to endoscope is demonstrated in the study by Kramer et al,8 colonoscopy patients with and without heartburn. Gastroenterology. published in this issue. In an impressive audit of nearly 500 000 2003;125(6):1670-1677. cases of GERD identified in Veteran Health Administration rec- 8. Kramer JR, Shakhatreh MH, Naik AD, Duan Z, El-Serag HB. Use and yield of ords, the authors found that those patients more likely to re- endoscopy in patients with uncomplicated gastroesophageal reflux disorder ceive an EGD in the first year after diagnosis were actually less [published online January 27, 2014]. JAMA Intern Med. doi:10.1001/ jamainternmed.2013.12756. likely to have either BE or esophageal cancer.8 Men older than 9. Dulai GS, Guha S, Kahn KL, Gornbein J, Weinstein WM. Preoperative 65 years, for example, were nearly 7-fold more likely to have prevalence of Barrett’s esophagus in esophageal adenocarcinoma: a systematic BE or esophageal cancer compared with a cohort of women review. Gastroenterology. 2002;122(1):26-33. younger than 50 years as the reference group, but these men 10. Chang JY, Locke GR III, McNally MA, et al.
    [Show full text]
  • Preface ...4 Scientific Program
    Preface . 4 Scientific Program . 6 Posters . 12 List of Speakers . 18 Information . 24 11 credit hours (CME) have been awarded to the Symposium 207 by the European Union of Medical Specialists (UEMS) - European Board of Gastroenterology . 3 13635_Falk_Brisbane_Symp_207_Prog_Inhalt.indd 3 30.03.17 10:49 Preface In recent years medicine has witnessed an astonishing paradigm shift . For decades it was believed that for most diseases the individual risk was defined by the genetic make-up, potentially modified by the environment and lifestyle-factors . It has now emerged that the gut microbiome plays an equally important role for many gastrointestinal and non-gastrointestinal disorders . This opens astonishing new avenues to understand and target disease mechanisms in particular in relation to immune mediated diseases but might be equally important for the prevention of disease . Thus the organisers Gerald Holtmann and Mark Morrison from Brisbane, Nicholas Talley from Newcastle, William Chey from Ann Arbor, and Peter Gibson from Melbourne in close collaboration with other experts in the field have developed a scientific program that brings together basic scientists and clinicians from many disciplines to define our current knowledge and define future directions that are relevant for the translation of this knowledge into clinical practice . On behalf of the scientific committee Prof . Gerald Holtmann, Brisbane 4 13635_Falk_Brisbane_Symp_207_Prog_Inhalt.indd 4 30.03.17 10:49 Symposium 207 Gut Microbiome and Mucosal or Systemic Dysfunction: Mechanisms, Clinical Manifestations and Interventions May 19 – 20, 2017 Brisbane Convention & Exhibition Centre Scientifi c Organization: Prof . Gerald Holtmann Brisbane, Australia Princess Alexandra Hospital University of Queensland 199 Ipswich Road Brisbane, QLD 4102, Australia Telephone: +617 31 76 77 92 Telefax: +617 31 76 51 11 Registration: E-Mail: g .holtmann@uq .edu .au Thursday, May 18, 2017 16 .00 – 21 .00 h Scientifi c Co-Organization: at the congress offi ce W .D .
    [Show full text]